Evidence map›Paper›PMID 37366273›Full record

ArticleCancer medicine2023

Prognostic and immune infiltration significance of ARID1A in TCGA molecular subtypes of gastric adenocarcinoma.

Zhenkun Zhang, Qiujing Li, Shanshan Sun, Jing Ye, Zhe Li, Zhengguo Cui, Qian Liu, Yujie Zhang, Sili Xiong, Shukun Zhang

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Genomic events stratifying prognosis of early gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024
    Article
  5. Review
  6. Cancers · 2024
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Zhenkun ZhangWeihai Municipal Hospital, Shandong University, Weihai, China.
Qiujing LiDepartment of Pathology, Weihai Municipal Hospital, Shandong University, Weihai, China.
Shanshan SunDepartment of Oncology, Weihai Municipal Hospital, Shandong University, Weihai, China.
Jing YeBinzhou Medical University, Yantai, China.
Zhe LiWeifang Medical College, Weifang, China.
Zhengguo CuiDepartment of Environmental Health, University of Fukui School of Medical Sciences, Fukui, Japan.
Qian LiuDepartment of Pathology, Weihai Municipal Hospital, Shandong University, Weihai, China.
Yujie ZhangDepartment of Pathology, Weihai Municipal Hospital, Shandong University, Weihai, China.
Sili XiongWeifang Medical College, Weifang, China.
Shukun ZhangDepartment of Pathology, Weihai Municipal Hospital, Shandong University, Weihai, China.ORCID 0000-0003-4184-5619
Shandong University · CNWeifang Medical University · CNBinzhou Medical University · CNUniversity of Fukui · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAT-rich interaction domain 1A (ARID1A) is an essential subunit of the switch/sucrose non-fermentable chromatin remodeling complex and is considered to be a tumor suppressor. The Cancer Genome Atlas (TCGA) molecular classification has deepened our understanding of gastric cancer at the molecular level. This study explored the significance of ARID1A expression in TCGA subtypes of gastric adenocarcinoma.

methodsWe collected 1248 postoperative patients with gastric adenocarcinoma, constructed tissue microarrays, performed immunohistochemistry for ARID1A, and obtained correlations between ARID1A and clinicopathological variables. We then carried out the prognostic analysis of ARID1A in TCGA subtypes. Finally, we screened patients by random sampling and propensity score matching method and performed multiplex immunofluorescence to explore the effects of ARID1A on CD4, CD8, and PD-L1 expression in TCGA subtypes.

resultsSeven variables independently associated with ARID1A were screened out: mismatch repair proteins, PD-L1, T stage, differentiation status, p53, E-cadherin, and EBER. The independent prognostic variables in the genomically stable (GS) subtype were N stage, M stage, T stage, chemotherapy, size, and ARID1A. PD-L1 expression was higher in the ARID1A negative group than in the ARID1A positive group in all TCGA subgroups. CD4 showed higher expression in the ARID1A negative group in most subtypes, while CD8 did not show the difference in most subtypes. When ARID1A was negative, PD-L1 expression was positively correlated with CD4/CD8 expression; while when ARID1A was positive, this correlation disappeared.

conclusionsThe negative expression of ARID1A occurred more frequently in the Epstein-Barr virus and microsatellite instability subtypes and was an independent adverse prognostic factor in the GS subtype. In the TCGA subtypes, ARID1A negative expression caused increased CD4 and PD-L1 expression, whereas CD8 expression appeared independent of ARID1A. The expression of CD4/CD8 induced by ARID1A negativity was accompanied by an increase in PD-L1 expression.

Indexed as

AdenocarcinomaEpstein-Barr Virus InfectionsStomach NeoplasmsB7-H1 AntigenDNA-Binding ProteinsHerpesvirus 4, HumanHumansPrognosisTranscription FactorsARID1A protein, humanB7-H1 AntigenDNA-Binding ProteinsTranscription FactorsARID1Agastric adenocarcinomaimmune infiltrationprognosisTCGA subtype

Identifiers

PMID37366273
PMCPMC10501255
OpenAlexW4382181426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.